BioSpace News Archive

Rothman Orthopaedic Institute, an internationally recognized orthopaedic practice, has recently launched their distinct, non-profit organization titled Rothman Orthopaedic Institute Foundation for Opioid Research & Education.

In a letter delivered today to the majority and minority leaders of Congress, the American Pharmacists Association requested immediate action to address the growing need to expand COVID-19 testing and immunization services by providing all pharmacists with temporary provider status in Medicare Part B.

Biogen (Nasdaq: BIIB) today announced there will be multiple data presentations from its Alzheimer’s disease (AD) clinical development portfolio, a virtual satellite symposium and AD PACE poster presentations at the Alzheimer’s Association International Conference (AAIC), which will be held online July 27-31. The company’s contributions to AAIC showcase its work to build a broad AD franchise across multiple targets and modalities, as well

BetterLife Pharma Inc. (“BetterLife” or the “Company”) (OTCQB:BETRF / CSE: BETR / FRA: NPAT) provides the following information about certain promotional activities at the request of OTC Markets. Recently, BetterLife has proactively engaged a number of entities to help raise its profile as an emerging biotechnology company and to raise awareness of its potential Interferon based Coivid-19 treatment. Towards this end, Betterlife entered into a con

Medifocus Inc. (TSXV-MFS) (“ Medifocus ” or the “ Company ”) today announced in accordance with Ontario Instrument 51-502 Temporary Exemption from Certain Corporate Finance Requirements of the Ontario Securities Commission (the “ Exemption Order ”), which was adopted for the purpose of providing certain filing and other relief to issuers in light of the challenges posted by the COVID-19 pandemic, that it will be delaying the filing of certain of its

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, today announced that it received written communication from the U.S. Food and Drug Administration (FDA) that the Company’s IGNITE DMD Phase I/II clinical trial remains on clinical hold. In November 2019, the FDA placed IGNITE DMD on clinical hold as the result of a serious adverse event (SAE) that occurre

Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, July 24 for the fourth quarter and the year ended March 31, 2020

Today, the U.S. Food and Drug Administration approved Tecartus (brexucabtagene autoleucel), a cell-based gene therapy for treatment of adult patients diagnosed with mantle cell lymphoma (MCL) who have not responded to or who have relapsed following other kinds of treatment. Tecartus, a chimeric antigen receptor (CAR) T cell therap

TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the Company plans to discuss initial data from the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for patients with mesothelin-expressing solid tumors in a premarket press release and webcast to be held on Monday, July 27 th , 2020. The Company will h

Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering diagnostics and expanded therapeutic options for cancer patients, announced that it will release its financial results for the second quarter 2020 after the stock market close on Monday, August 10, 2020. Management will host a teleconference the same day at 4:30 p.m. Eastern Time (ET) to discuss the results.